Outsourced Pharma White Papers
-
State-Of-The-Art Bispecific Antibody Development
10/11/2022
The promise of bispecific antibodies stems from their off-the-shelf nature and ability to bind to two or more different targets or epitopes, thereby performing multiple functions.
-
Can Yeast Be The Future Of Efficient Subunit Vaccine Manufacturing?
9/11/2023
To aid in the manufacturing of new vaccines, Pichia pastoris yeast, a promising protein expression system, could be the perfect solution.
-
Five Essentials For Accurate Oligonucleotide Chemistry
3/4/2024
Explore five key areas in oligonucleotide chemistry where improvements will have a huge influence on your synthesis quality.
-
Optimizing End-To-End Contract Analytical Support For Cell And Gene Therapies
7/11/2024
The development and production CGTs present unparalleled complexities. Learn how a partner with robust end-to-end services can help you overcome challenges at every step of the drug lifecycle.
-
Quantitation Of Monoclonal Antibodies In Serum
2/8/2024
Monoclonal antibodies (mAbs) are a rapidly growing group of targeted therapeutics. Gain insight into the importance of optimized bioanalytical assay platforms for mAb development.
-
Establishing Commercial Manufacturing Services For ADCs
6/3/2024
Explore how one organization built upon 15+ years of experience and an extensive knowledge base of biologics manufacturing to establish commercial-scale ADC manufacturing capabilities.
-
Eliminating USP <88> In Vivo Animal Bioreactivity Testing For Polymer Characterization
8/25/2023
There has been growing awareness about the environmental and ethical implications of plastics used in bioprocessing. The time for a shift to well-studied, proven in vitro cytotoxicity testing is now.
-
Switching To Direct-To-Patient Rapidly In The EU
10/4/2022
Explore the logistical risk management factors to consider when deciding to switch to direct-to-patient shipments in the EU.
-
The Business Case For Pharmaceutical Continuous Manufacturing
6/2/2023
Examine a step-by-step approach outlining the business cases that support adopting continuous manufacturing, with considerations for innovators, generics manufacturers, CDMOs, and OTC suppliers.
-
Efficient, Large-Scale Transfection Of T-Cells Using Flowfect® Technology
2/26/2023
The objective of this study was to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post-transfection growth using Kytopen’s Flowfect® technology.